Search hospitals > New Jersey > Lakewood
Monmouth Medical Center - Southern Campus
Claim this profileLakewood, New Jersey 08701
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Colorectal Cancer
46 reported clinical trials
15 medical researchers
Summary
Monmouth Medical Center - Southern Campus is a medical facility located in Lakewood, New Jersey. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Colorectal Cancer and other specialties. Monmouth Medical Center - Southern Campus is involved with conducting 46 clinical trials across 100 conditions. There are 15 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Patrick M. Boland.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderER positive
HER2 positive
PR positive
Top PIs
Howard S. HochsterRutgers Cancer Institute of New Jersey4 years of reported clinical research
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
Missak Haigentz, MDRutgers Cancer Institute of New Jersey3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
14 reported clinical trials
23 drugs studied
Eugenia Girda, MDRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Cancer
Studies Ovarian Cancer
14 reported clinical trials
29 drugs studied
Patrick M. BolandRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
9 reported clinical trials
18 drugs studied
Clinical Trials running at Monmouth Medical Center - Southern Campus
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Diffuse Large B-Cell Lymphoma
Bladder Cancer
Colon Cancer
Gallbladder Cancer
Lymphoma
Recurrence
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Monmouth Medical Center - Southern Campus?
Monmouth Medical Center - Southern Campus is a medical facility located in Lakewood, New Jersey. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Colorectal Cancer and other specialties. Monmouth Medical Center - Southern Campus is involved with conducting 46 clinical trials across 100 conditions. There are 15 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Patrick M. Boland.